Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).

Ghilardi G, Stussi G, Mazzucchelli L, Röcken C, Rossi D, Gerber B.

Amyloid. 2019 Sep;26(3):173-174. doi: 10.1080/13506129.2019.1615428. Epub 2019 Jun 22. No abstract available.

PMID:
31232114
2.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM, Bertoni F.

Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.

3.

Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.

Benzarti S, Daskalakis M, Feller A, Bacher VU, Schnegg-Kaufmann A, Rüfer A, Holbro A, Schmidt A, Benz R, Solenthaler M, Stussi G, Arndt V, Bonadies N; NICER Working Group.

Cancer Epidemiol. 2019 Apr;59:51-57. doi: 10.1016/j.canep.2019.01.003. Epub 2019 Jan 25.

PMID:
30690330
4.

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.

Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK).

Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.

5.

Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.

Ghilardi G, Pabst T, Jeker B, Müller R, Cairoli A, Müller AMS, Bargetzi M, Hitz F, Baldomero H, Heim D, Schmidt A, Rossi D, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg JR, Stussi G, Kleber M, Gerber B; Swiss Blood Stem Cell Transplantation Registry.

Bone Marrow Transplant. 2019 Jul;54(7):1029-1037. doi: 10.1038/s41409-018-0379-y. Epub 2018 Nov 2.

PMID:
30390061
6.

Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016.

Passweg JR, Baldomero H, Ansari M, Baerlocher GM, Bargetzi M, Chalandon Y, Duchosal MA, Gerull S, Güngör T, Halter JP, Heim D, Hess U, Leibundgut K, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, For The Swiss Blood Stem Cell Transplantation Group Sbst.

Swiss Med Wkly. 2018 Mar 1;148:w14589. doi: 10.4414/smw.2018.14589. eCollection 2018.

7.

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A.

Haematologica. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22. No abstract available.

8.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.

9.

Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.

Schnegg-Kaufmann A, Feller A, Baldomero H, Rovo A, Manz MG, Gregor M, Efthymiou A, Bargetzi M, Hess U, Spertini O, Chalandon Y, Passweg JR, Stussi G, Arndt V, Bonadies N; NICER Working Group.

Cancer Epidemiol. 2018 Feb;52:55-62. doi: 10.1016/j.canep.2017.11.008. Epub 2017 Dec 7.

PMID:
29223104
10.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

11.

Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland.

Glier H, Heijnen I, Hauwel M, Dirks J, Quarroz S, Lehmann T, Rovo A, Arn K, Matthes T, Hogan C, Keller P, Dudkiewicz E, Stüssi G, Fernandez P; Swiss Cytometry Society.

J Immunol Methods. 2017 Jul 29. pii: S0022-1759(17)30205-3. doi: 10.1016/j.jim.2017.07.013. [Epub ahead of print]

12.

Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.

Rossi D, Gerber B, Stüssi G.

Leuk Lymphoma. 2017 Jul;58(7):1548-1560. doi: 10.1080/10428194.2016.1250264. Epub 2016 Nov 3. Review.

PMID:
27808579
13.

Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.

Gerber B, Alberio L, Rochat S, Stenner F, Manz MG, Buser A, Schanz U, Stussi G.

Transfusion. 2016 Oct;56(10):2426-2437. doi: 10.1111/trf.13690. Epub 2016 Jun 24.

PMID:
27339466
14.

Combination therapy for multidrug-resistant cytomegalovirus disease.

Stuehler C, Stüssi G, Halter J, Nowakowska J, Schibli A, Battegay M, Dirks J, Passweg J, Heim D, Rovo A, Kalberer C, Bucher C, Weisser M, Dumoulin A, Hirsch HH, Khanna N.

Transpl Infect Dis. 2015 Oct;17(5):751-5. doi: 10.1111/tid.12435. Epub 2015 Oct 3.

PMID:
26432076
15.

Bone Marrow Involvement in Unknown Acute Myeloid Leukemia Detected by 18F-FDG PET/MRI.

Paone G, Stüssi G, Pons M, Giovanella L, Ceriani L.

Clin Nucl Med. 2015 Oct;40(10):e486-7. doi: 10.1097/RLU.0000000000000898.

PMID:
26204209
16.

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F.

Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26.

17.

Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.

Kirsch M, Mitchell SA, Dobbels F, Stussi G, Basch E, Halter JP, De Geest S.

Eur J Oncol Nurs. 2015 Feb;19(1):66-74. doi: 10.1016/j.ejon.2014.07.007. Epub 2014 Sep 1.

PMID:
25190633
18.

Differences in health behaviour between recipients of allogeneic haematopoietic SCT and the general population: a matched control study.

Kirsch M, Götz A, Halter JP, Schanz U, Stussi G, Dobbels F, De Geest S.

Bone Marrow Transplant. 2014 Sep;49(9):1223-30. doi: 10.1038/bmt.2014.142. Epub 2014 Jul 21.

PMID:
25046214
19.

Reply to Canet et al: Acute kidney injury in critically ill allo-HSCT recipients.

Benz R, Stussi G.

Bone Marrow Transplant. 2014 Aug;49(8):1123. doi: 10.1038/bmt.2014.101. Epub 2014 May 12. No abstract available.

PMID:
24820214
20.

Unusual case of progressive multifocal leukoencephalopathy after allogeneic hematopoietic stem-cell transplantation.

Berger MD, Meisel A, Andres M, Schanz U, Schwarz U, Stussi G.

J Clin Oncol. 2014 Mar 20;32(9):e33-4. doi: 10.1200/JCO.2012.47.5194. Epub 2014 Jan 13. No abstract available.

PMID:
24419131
21.

Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.

Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, Vermont C, Ahmad I, Shaw PJ, Telles da Cunha JM, Schlegel PG, Hough R, Fasth A, Kentouche K, Gruhn B, Fernandes JF, Lachance S, Bredius R, Resnick IB, Belohradsky BH, Gennery A, Fischer A, Gaspar HB, Schanz U, Seger R, Rentsch K, Veys P, Haddad E, Albert MH, Hassan M; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation.

Lancet. 2014 Feb 1;383(9915):436-48. doi: 10.1016/S0140-6736(13)62069-3. Epub 2013 Oct 23.

PMID:
24161820
22.

Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT.

Benz R, Schanz U, Maggiorini M, Seebach JD, Stussi G.

Bone Marrow Transplant. 2014 Jan;49(1):62-5. doi: 10.1038/bmt.2013.141. Epub 2013 Sep 23.

PMID:
24056739
23.

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.

Marek A, Stern M, Chalandon Y, Ansari M, Ozsahin H, Güngör T, Gerber B, Kühne T, Passweg JR, Gratwohl A, Tichelli A, Seger R, Schanz U, Halter J, Stussi G; Swiss Blood Stem Cell Transplantation.

Bone Marrow Transplant. 2014 Jan;49(1):55-61. doi: 10.1038/bmt.2013.132. Epub 2013 Sep 16.

PMID:
24037023
24.

Prognostic impact of monocyte count at presentation in mantle cell lymphoma.

von Hohenstaufen KA, Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casaluci G, Stathis A, Ghielmini M, Stussi G, Cavalli F, Gaidano G, Zucca E.

Br J Haematol. 2013 Aug;162(4):465-73. doi: 10.1111/bjh.12409. Epub 2013 Jun 29.

PMID:
23808798
25.

Brief Exercise Increases Peripheral Blood NK Cell Counts without Immediate Functional Changes, but Impairs their Responses to ex vivo Stimulation.

Millard AL, Valli PV, Stussi G, Mueller NJ, Yung GP, Seebach JD.

Front Immunol. 2013 May 29;4:125. doi: 10.3389/fimmu.2013.00125. eCollection 2013.

26.

Extranodal NK/T-cell lymphoma with leukaemic presentation.

Gobba S, Moccia A, Stussi G, Mazzucchelli L, Zucca E, Espeli V.

Br J Haematol. 2013 Jun;161(6):754. doi: 10.1111/bjh.12360. Epub 2013 May 7. No abstract available.

PMID:
23647401
27.

The changing paradigm of chronic lymphocytic leukemia management.

Lobetti-Bodoni C, Bertoni F, Stussi G, Cavalli F, Zucca E.

Eur J Intern Med. 2013 Jul;24(5):401-10. doi: 10.1016/j.ejim.2013.03.009. Epub 2013 Apr 11. Review.

PMID:
23583413
28.

Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07).

Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chalandon Y; Swiss Group for Clinical Cancer Research (SAKK).

Leuk Lymphoma. 2014 Jan;55(1):87-91. doi: 10.3109/10428194.2013.790540. Epub 2013 May 2.

PMID:
23547838
29.

Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.

Passweg JR, Baldomero H, Bargetzi M, Bucher C, Chalandon Y, Duchosal MA, Gratwohl A, Güngör T, Hess U, Leibundgut K, de Faveri GN, Ozsahin H, Pabst T, Renner C, Stern M, Stussi G, Schanz U; SBST (Swiss Blood Stem Cell Transplantation Group).

Swiss Med Wkly. 2013 Feb 22;143:w13757. doi: 10.4414/smw.2013.13757. eCollection 2013.

30.

Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH.

Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Uhr M, Stussi G, Kwee I, Cavalli F, Gaidano G, Zucca E, Bertoni F.

Ann Oncol. 2013 May;24(5):1378-84. doi: 10.1093/annonc/mds646. Epub 2013 Jan 31.

PMID:
23372049
31.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B.

Blood. 2012 Dec 6;120(24):4706-11. doi: 10.1182/blood-2012-04-420596. Epub 2012 Oct 9.

32.

Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT.

Gerull S, Stern M, Ben Aissa A, Manz MG, Schanz U, Stussi G, Chalandon Y, Passweg J, Mohty B.

Bone Marrow Transplant. 2013 Mar;48(3):408-13. doi: 10.1038/bmt.2012.167. Epub 2012 Sep 3.

PMID:
22941381
33.

Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole.

Gerber B, Guggenberger R, Fasler D, Nair G, Manz MG, Stussi G, Schanz U.

Blood. 2012 Sep 20;120(12):2390-4. Epub 2012 Aug 2.

34.

ABO-incompatible kidney transplantation.

Fehr T, Stussi G.

Curr Opin Organ Transplant. 2012 Aug;17(4):376-85. doi: 10.1097/MOT.0b013e328355f013. Review.

PMID:
22790072
35.

Castleman's disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level?

Schumacher A, Jacomella V, Stüssi G, Amann-Vesti B, Corti N, Husmann M.

Vasa. 2012 Mar;41(2):145-8. doi: 10.1024/0301-1526/a000178.

PMID:
22403134
37.

Optimised radiological diagnosis of hepatic fungal infection during the treatment of leukemia.

Petrausch U, Frauenfelder T, Mueller NJ, Arn K, Stussi G, Schanz U.

Mycoses. 2012 Sep;55(5):447-53. doi: 10.1111/j.1439-0507.2012.02172.x. Epub 2012 Feb 10.

PMID:
22320220
38.

Reversibility of spur cell anemia.

Gerber B, Stussi G.

Blood. 2011 Oct 20;118(16):4304. No abstract available.

39.

Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption.

Wahrmann M, Schiemann M, Marinova L, Körmöczi GF, Derfler K, Fehr T, Stussi G, Böhmig GA.

Nephrol Dial Transplant. 2012 May;27(5):2122-9. doi: 10.1093/ndt/gfr610. Epub 2011 Nov 15.

40.

Late effects on haemostasis after haematopoietic stem cell transplantation.

Stussi G, Tsakiris DA.

Hamostaseologie. 2012;32(1):63-6. doi: 10.5482/ha-1184. Epub 2011 Nov 15.

PMID:
22083512
41.

Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms.

Bettens F, Passweg J, Schanz U, Chalandon Y, Heim D, Güngör T, Stussi G, Nicoloso G, Baldomero H, Gratwohl A, Tiercy JM.

Biol Blood Marrow Transplant. 2012 Apr;18(4):608-16. doi: 10.1016/j.bbmt.2011.09.011. Epub 2011 Oct 1.

42.

Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.

Berger MD, Gerber B, Arn K, Senn O, Schanz U, Stussi G.

Haematologica. 2012 Jan;97(1):116-22. doi: 10.3324/haematol.2011.047035. Epub 2011 Sep 20.

43.

Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.

Samaras P, Blickenstorfer M, Haile SR, Siciliano RD, Petrausch U, Mischo A, Zweifel M, Honegger H, Schanz U, Stussi G, Taverna C, Bauer S, Knuth A, Stenner-Liewen F, Renner C.

Swiss Med Wkly. 2011 May 31;141:w13203. doi: 10.4414/smw.2011.13203. eCollection 2011.

44.

Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia.

Zeidler K, Arn K, Senn O, Schanz U, Stussi G.

Transfusion. 2011 Nov;51(11):2269-76. doi: 10.1111/j.1537-2995.2011.03147.x. Epub 2011 Apr 22.

PMID:
21517892
45.

Erythroleukaemia at second glance.

Arn KD, Dazzi H, Went P, Goede JS, Stussi G.

Eur J Haematol. 2011 Apr;86(4):358-9. doi: 10.1111/j.1600-0609.2010.01574.x. Epub 2011 Feb 18. No abstract available.

PMID:
21198865
46.

Complement inhibition to treat myocardial infarction?

Gerber B, Kyburz T, Reinhart WH, Bonetti PO, Stussi G.

BMJ Case Rep. 2011 Apr 26;2011. pii: bcr0120113701. doi: 10.1136/bcr.01.2011.3701.

47.

Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, Stenner-Liewen F.

Oncology. 2010;79(1-2):93-7. doi: 10.1159/000320604. Epub 2010 Nov 15.

48.

Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.

Mueller RJ, Stussi G, Puga Yung G, Nikolic M, Soldini D, Halter J, Meyer-Monard S, Gratwohl A, Passweg JR, Odermatt B, Schanz U, Biedermann BC, Seebach JD.

Haematologica. 2011 Jan;96(1):119-27. doi: 10.3324/haematol.2010.030288. Epub 2010 Oct 7.

49.

[Thrombocytopenia].

Sidi R, Rodak R, Stüssi G.

Praxis (Bern 1994). 2010 Jul 28;99(15):881-92; quiz 891. doi: 10.1024/1661-8157/a000207. German. No abstract available.

PMID:
20715001
50.

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Samaras P, Blickenstorfer M, Siciliano RD, Haile SR, Buset EM, Petrausch U, Mischo A, Honegger H, Schanz U, Stussi G, Stahel RA, Knuth A, Stenner-Liewen F, Renner C.

Ann Hematol. 2011 Jan;90(1):89-94. doi: 10.1007/s00277-010-1036-8. Epub 2010 Aug 13.

PMID:
20706722

Supplemental Content

Loading ...
Support Center